TY - JOUR
T1 - Retraction notice to “Use of ivermectin in the treatment of Covid-19
T2 - A pilot trial” [Toxicol. Rep. 8 (2021) 505–510] (Toxicology Reports (2021) 8 (505–510), (S2214750021000445), (10.1016/j.toxrep.2021.03.003))
AU - Pott-Junior, Henrique
AU - Paoliello, Mônica Maria Bastos
AU - Miguel, Alice de Queiroz Constantino
AU - da Cunha, Anderson Ferreira
AU - de Melo Freire, Caio Cesar
AU - Neves, Fábio Fernandes
AU - da Silva de Avó, Lucimar Retto
AU - Roscani, Meliza Goi
AU - dos Santos, Sigrid De Sousa
AU - Chach´, Silvana Gama Florêncio
N1 - Publisher Copyright:
© 2022 The Authors
PY - 2022/1
Y1 - 2022/1
N2 - This article has been retracted: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/about/our-business/policies/article-withdrawal). The article has been retracted at the request of the Founding Editor, Prof. Lawrence H. Lash, on the basis that there is clear evidence that the findings are unreliable: https://publicationethics.org/files/retraction-guidelines-cope.pdf. Additional external review of this published paper raised several concerns. While a properly conducted clinical trial is certainly welcome, the experimental design of this study lacks sufficient details for some of the methods and approaches, uses inappropriate or inadequate statistical analysis, and presents unclear data interpretation. The conclusions and statements of the authors cannot be readily supported by the information presented in the paper. Additionally, no reference is made to the well-known controversies that surrounded the recommended use of ivermectin to treat infections with COVID-19. https://www.nature.com/articles/d41586-020-01695-w; https://www.the-scientist.com/news-opinion/surgisphere-sows-confusion-about-another-unproven-covid19-drug-67635 The omission of any discussion of these controversies in the present paper makes the paper misleading and unacceptable.
AB - This article has been retracted: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/about/our-business/policies/article-withdrawal). The article has been retracted at the request of the Founding Editor, Prof. Lawrence H. Lash, on the basis that there is clear evidence that the findings are unreliable: https://publicationethics.org/files/retraction-guidelines-cope.pdf. Additional external review of this published paper raised several concerns. While a properly conducted clinical trial is certainly welcome, the experimental design of this study lacks sufficient details for some of the methods and approaches, uses inappropriate or inadequate statistical analysis, and presents unclear data interpretation. The conclusions and statements of the authors cannot be readily supported by the information presented in the paper. Additionally, no reference is made to the well-known controversies that surrounded the recommended use of ivermectin to treat infections with COVID-19. https://www.nature.com/articles/d41586-020-01695-w; https://www.the-scientist.com/news-opinion/surgisphere-sows-confusion-about-another-unproven-covid19-drug-67635 The omission of any discussion of these controversies in the present paper makes the paper misleading and unacceptable.
UR - http://www.scopus.com/inward/record.url?scp=85129594812&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85129594812&partnerID=8YFLogxK
U2 - 10.1016/j.toxrep.2022.04.009
DO - 10.1016/j.toxrep.2022.04.009
M3 - Comment/debate
AN - SCOPUS:85129594812
SN - 2214-7500
VL - 9
SP - 1023
JO - Toxicology Reports
JF - Toxicology Reports
ER -